Literature DB >> 16328039

Rb-loss is associated with high malignancy in chondrosarcoma.

M Röpke1, C Boltze, B Meyer, H W Neumann, A Roessner, R Schneider-Stock.   

Abstract

Loss of function of the human retinoblastoma gene (Rb) is a frequent genetic abnormality in human malignancies and causes a disturbance in the cell cycle and loss of normal proliferation and differentiation. We studied the loss of heterozygosity (LOH) of the Rb gene in 31 formalin-fixed, paraffin-embedded cartilaginous tumors using polymerase chain reaction. The tumors were subdivided into 8 cases of dedifferentiated (DD) chondrosarcoma, 17 cases of conventional chondrosarcoma (nine grade 1, seven grade 2 and one grade 3), 4 enchondromas and 2 chondroblastomas. Both components of DD chondrosarcoma, the low-grade and anaplastic components, were separated by a microdissection approach. The genetic data were correlated with the expression of the Rb protein examined by Rb immunohistochemistry. We found Rb-LOH in one grade 3 chondrosarcoma, and in the anaplastic component in 7 of 8 cases of DD chondrosarcoma (89% of all high-grade chondrosarcomas). All tumors with Rb-LOH were immunohistochemically Rb-negative. The only case of DD chondrosarcoma negative for Rb-LOH in both components of the tumor also showed weak expression of the Rb protein in the anaplastic component. All benign cartilaginous tumors, low-grade chondrosarcomas and low-grade tumor components of DD chondrosarcomas were negative regarding Rb-LOH but positive in Rb immunohistostaining. We concluded that Rb-LOH predominantly occurs in high-grade chondrosarcomas. However, it is not a marker for identifying low-grade tumors with a tendency towards progression or local recurrence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16328039     DOI: 10.3892/or.15.1.89

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

Review 1.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

2.  Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation.

Authors:  A S Landman; P S Danielian; J A Lees
Journal:  Oncogene       Date:  2012-11-12       Impact factor: 9.867

3.  Dedifferentiated chondrosarcoma with leukocytosis and elevation of serum G-CSF. A case report.

Authors:  Akio Sakamoto; Hidetaka Yamamoto; Kazuhiro Tanaka; Shuichi Matsuda; Katsumi Harimaya; Yoshinao Oda; Masazumi Tsuneyoshi; Yukihide Iwamoto
Journal:  World J Surg Oncol       Date:  2006-07-04       Impact factor: 2.754

Review 4.  Chondrosarcoma: biology, genetics, and epigenetics.

Authors:  Warren A Chow
Journal:  F1000Res       Date:  2018-11-20

5.  [Effects of tumor suppressor gene TCF21 on the proliferation, migration and apoptosis of A549 cells].

Authors:  Song Hu; Nuo Yang; Mingwu Chen; Jianji Guo; Lei Xian
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-04

6.  Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution.

Authors:  Ruoyu Miao; Edwin Choy; Kevin A Raskin; Joseph H Schwab; Gunnlaugur Petur Nielsen; Vikram Deshpande; Ivan Chebib; Thomas F DeLaney; Francis J Hornicek; Gregory M Cote; Yen-Lin E Chen
Journal:  Sarcoma       Date:  2019-12-13

7.  A genetic model for central chondrosarcoma evolution correlates with patient outcome.

Authors:  Peter Van Loo; Adrienne M Flanagan; William Cross; Iben Lyskjær; Tom Lesluyes; Steven Hargreaves; Anna-Christina Strobl; Christopher Davies; Sara Waise; Shadi Hames-Fathi; Dahmane Oukrif; Hongtao Ye; Fernanda Amary; Roberto Tirabosco; Craig Gerrand; Toby Baker; David Barnes; Christopher Steele; Ludmil Alexandrov; Gareth Bond; Paul Cool; Nischalan Pillay
Journal:  Genome Med       Date:  2022-08-30       Impact factor: 15.266

8.  Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.

Authors:  Yvonne M Schrage; Suzanne Lam; Aart G Jochemsen; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  J Cell Mol Med       Date:  2008-06-27       Impact factor: 5.310

9.  The molecular pathogenesis of dedifferentiated chondrosarcoma.

Authors:  Akio Sakamoto
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

Review 10.  Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype.

Authors:  Agnieszka Zając; Sylwia K Król; Piotr Rutkowski; Anna M Czarnecka
Journal:  Cancers (Basel)       Date:  2021-03-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.